Quintiles acquires Targeted Molecular Diagnostics

The addition of Targeted Molecular Diagnostics (TMD) to Quintiles’s global central laboratories is said to strengthen Quintiles’s service offerings in oncology. It is also expected to provide strong capabilities in tissue-based testing, a critical component of the modern oncology drug development process.

TMD’s biomarker technology will help Quintiles’s customers better understand how their drugs work and in which populations they’re most likely to perform best.

Tom Wollman, senior vice president of Quintiles global central laboratories, said: “This acquisition is a logical addition to Quintiles’s service offerings. It provides us with advanced in-house pathology capabilities, including telepathology. Most importantly, TMD’s knowledge in biomarker expression analysis adds significant new proficiencies sought by our customers.”